文章摘要
王雪芹,汪新体,方 侃,胡 元,曾 敏,彭旭玲.肺表面活性物质对新生儿重症肺炎血清ATⅢ、D-D、SP-B的影响及疗效观察[J].,2019,19(13):2563-2566
肺表面活性物质对新生儿重症肺炎血清ATⅢ、D-D、SP-B的影响及疗效观察
Effect of Pulmonary Surfactant on Serum ATⅢ, D-D and SP-B in Neonatal Severe Pneumonia and Its Curative Effect
投稿时间:2018-12-07  修订日期:2018-12-28
DOI:10.13241/j.cnki.pmb.2019.13.037
中文关键词: 肺表面活性物质  重症肺炎  新生儿  血清抗凝血酶Ⅲ  D-二聚体  肺表面活性蛋白B
英文关键词: Pulmonary surfactant  Severe pneumonia  Neonatal  Serum antithrombin III  D-dimer  Pulmonary surfactant protein B
基金项目:湖北省自然科学基金项目(2005ABA079)
作者单位E-mail
王雪芹 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000 zhoudj64@163.com 
汪新体 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000  
方 侃 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000  
胡 元 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000  
曾 敏 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000  
彭旭玲 十堰市太和医院(湖北医院学院附属医院) 湖北 十堰 442000  
摘要点击次数: 12
全文下载次数: 25
中文摘要:
      摘要 目的:探讨肺表面活性物质(PS)对新生儿重症肺炎血清抗凝血酶Ⅲ(ATⅢ)、D-二聚体(D-D)、肺表面活性蛋白B(SP-B)的影响及疗效。方法:选择本院2014年3月到2016年3月收治的重症肺炎新生儿62例进行回顾性分析,采用系统随机的方法分为观察组和对照组,每组各31例。对照组使用常规通气治疗,观察组在对照组基础上给予肺表面活性物质治疗。比较分析两组患者治疗后的临床疗效、机械通气时间及氧暴露时间及治疗前后的肺氧合功能、血清ATⅢ、D-D、SP-B表达水平。结果:治疗后,观察组患者总有效率为87.10%,明显高于对照组(70.97%),差异有统计学意义(P<0.05)。治疗前,两组患儿氧和指数(OI)及肺泡氧分压比值(a/APO2)表达水平比较无显著性差异(P>0.05)。治疗后24h、48h、72h,两组患儿OI及a/APO2表达水平较治疗前均得到了显著(P<0.05),且观察组OI及a/APO2表达水平改善情况显著优于对照组(P<0.05)。治疗前,两组患儿血清ATⅢ、D-D、SP-B表达水平比较无显著性差异(P>0.05)。治疗后,两组患儿血清D-D表达水平较治疗前显著降低(P<0.05),血清ATⅢ、SP-B表达水平较治疗前显著升高(P<0.05),且观察组血清D-D表达水平显著低于对照组(P<0.05),血清ATⅢ、SP-B表达水平显著高于对照组(P<0.05)。治疗后,观察组患儿的机械通气时间及氧暴露时间均明显低于对照组患儿,差异有统计学意义(P<0.05)。结论:肺表面活性物质能够有效的提高治疗疗效,且可以有效的改善患者血清肺氧合功能及血清ATⅢ、D-D、SP-B表达水平。
英文摘要:
      ABSTRACT Objective: To explore the Effects of pulmonary surfactant (PS) on serum antithrombin Ⅲ (ATⅢ), D-dimer (D-D) and pulmonary surfactant protein B (SP-B) in neonatal severe pneumonia and its curative effect. Methods: 62 cases of neonates with severe pneumonia treated in our hospital from March 2014 to March 2016 were retrospectively analyzed. The patients were randomly divided into observation group and control group, each group of 31 cases. The control group was treated with conventional ventilation. The observation group was treated with pulmonary surfactant on the control group. The clinical efficacy, mechanical ventilation time and oxygen exposure time, lung oxygenation function, serum ATⅢ, D-D and SP-B expression levels were compared between the two groups after treatment. Results: After treatment, the total effective rate of the observation group was 87.10%, significantly higher than the control group (70.97%), the difference was statistically significant (P <0.05). There was no significant difference in the expression of oxygen and index (OI) and alveolar oxygen partial pressure (a / APO2) between the two groups before treatment (P> 0.05). The expression of OI and a / APO2 in the two groups was significantly higher than that in the control group (P <0.05) at 24 h, 48 h and 72 h after treatment, and the improvement of OI and a / APO2 expression in the observation group was significantly better than that in the control group P <0.05).There was no significant difference in the levels of serum ATⅢ, D-D and SP-B between the two groups before treatment (P> 0.05). After treatment, the levels of serum DD in the two groups were significantly lower than those before treatment (P <0.05). The levels of serum ATⅢ and SP-B were significantly higher than those before treatment (P <0.05), and the level of serum DD was significantly (P <0.05). The levels of serum ATⅢ and SP-B were significantly higher than those of the control group (P <0.05). After treatment, the ventilation time and oxygen exposure time of the observation group were significantly lower than those of the control group, the difference was statistically significant (P <0.05). Conclusion: Pulmonary surfactant can effectively improve the therapeutic effect, and can effectively improve the serum pulmonary oxygenation function and serum AT Ⅲ, D-D, SP-B expression levels.
查看全文   查看/发表评论  下载PDF阅读器
关闭